Global Information
회사소개 | 문의 | 비교리스트

조울증 시장 : 성장, 동향, 예측(2019-2024년)

Bipolar Disorder Market - Growth, Trends, and Forecast (2019 - 2024)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2019년 05월 상품 코드 871392
페이지 정보 영문
가격
US $ 4,250 ₩ 5,110,000 PDF (Single User License)
US $ 4,750 ₩ 5,711,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,215,000 PDF (Site License)
US $ 7,500 ₩ 9,018,000 PDF (Corporate License)


조울증 시장 : 성장, 동향, 예측(2019-2024년) Bipolar Disorder Market - Growth, Trends, and Forecast (2019 - 2024)
발행일 : 2019년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 조울증(Bipolar Disorder) 시장에 대해 조사했으며, 시장 개요 및 성장 촉진요인과 저해요인, 약물 클래스·작용 메커니즘·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보에 대해 정리했습니다.

목차

제1장 서론

  • 연구 성과
  • 조사 가정
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 조울증 이환율 증가
    • 정부기관의 계발에 의한 정책 증가
    • 기술 진보
  • 시장 성장 저해요인
    • 조울증 약과 관련된 부작용
    • 조울증의 오진
  • Porter’s Five Forces 분석
    • 신규 참여업체의 위협
    • 바이어/소비자의 협상력
    • 공급업체의 협상력
    • 대체 제품의 위협
    • 업계내의 경쟁

제5장 시장 세분화

  • 약물 클래스별
    • 기분안정제
    • 항경련제
    • 항정신병제
    • 항우울제
    • 기타
  • 작용 메커니즘별
    • 선택적 세로토닌 재흡수 억제제
    • 세로토닌 노르에피네프린 재흡수 억제제
    • 삼환계 항우울제
    • 베타 차단제
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • AbbVie Inc.
    • Allergan PLC
    • AstraZeneca Plc
    • Eli Lilly and Company
    • GlaxoSmithKline Plc
    • Janssen Pharmaceuticals Inc.
    • Novartis AG
    • Otsuka Holdings Co. Ltd
    • Pfizer Inc.

제7장 시장 기회 및 향후 동향

KSM 19.07.01

Market Overview

The major factors for the growth of the bipolar disorder market include the increasing prevalence of the bipolar disorder, rising initiatives by government institutes to increase the awareness, and technological advancements.

There is an increasing prevalence of bipolar disorder owing to the various risk factors such as high stress, substance abuse, and others. According to the estimates of the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, the prevalence of bipolar disorder across the world varies from 0.3 to 1.2% by country. In 2017 around 46 million people in the world had bipolar disorder, with 52% and 48% being female and male, respectively. The typical age of onset is the late teens or the early 20s, and a history of depression is common in people diagnosed with bipolar. Men and women are affected by bipolar disorder in equal numbers. In women, the first episode is typically manic, while men typically experience a depressive episode first. Hence, the rise in the cases of the disease and the increasing need to manage them effectively has led to the growth of the bipolar disorder market.

Scope of the Report

As per the scope of this report, bipolar disorder is a mental illness marked by extreme shifts in mood. Symptoms may include an extremely elevated mood called mania, and also episodes of depression. Bipolar disorder is also known as bipolar disease or manic depression. People with bipolar disorder may have trouble managing everyday life tasks at school or work, or maintaining relationships. There's no cure, but there are many treatment options available that can help with managing the symptoms.

Key Market Trends

Antipsychotic Drugs is expected to be the Fastest Growing Segment Over the Forecast Period

Antipsychotic medications are used as a short-term treatment for bipolar disorder to control psychotic symptoms, such as hallucinations, delusions, or mania symptoms. These symptoms may occur during acute mania or severe depression. Some also treat bipolar depression, and several have demonstrated long-term value in preventing future episodes of mania or depression. In people with bipolar disorder, antipsychotics are also used "off label" as sedatives, for insomnia, for anxiety, and/or for agitation. Often, they are taken with a mood-stabilizing drug and can decrease the symptoms of mania until mood stabilizers take full effect. Some antipsychotics seem to help stabilize moods on their own. As a result, they may be used alone as a long-term treatment for people who do not tolerate or respond to lithium and anticonvulsants. A few antipsychotic drugs include aripiprazole (Abilify), asenapine (Saphris), cariprazine (Vraylar), clozapine (Clozaril), lurasidone (Latuda), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and ziprasidone (Geodon). Hence, due to the above-mentioned reasons, the market for antipsychotic drugs is expected to grow and further lead to the growth in the Bipolar Disorder Market.

North America is Expected to Dominate the Market

North America is found to hold a major share for the bipolar disorder market and is expected to show a similar trend over the forecast period, without significant fluctuations. Due to the increasing cases of bipolar disorder and the presence of better healthcare infrastructure, the market is expected to witness high growth over the forecast period. According to the data published by the National Alliance on Mental Illness, around 1 in 5 adults in the United States experiences mental illness in a given year. Hospitalization is required for severe episodes of mania and depression to protect the patients from injuring themselves or others. According to the NIMH, bipolar I disorder is characterized in part by manic symptoms that are so severe that the person needs immediate hospital care. There is a huge need to tackle bipolar disorder, as it is an increasing problem, and hence, the market for bipolar disorder is expected to grow during the forecast period.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are AbbVie Inc., Allergan PLC, AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline Plc, Janssen Pharmaceuticals Inc., Novartis AG, Otsuka Holdings Co. Ltd, and Pfizer Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Bipolar Disorder
    • 4.2.2 Rising initiative by Government Institutes to Increase the Awareness
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Bipolar Drugs
    • 4.3.2 Misdiagnosis of Bipolar Disorder
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Mood stabilizer
    • 5.1.2 Anticonvulsant
    • 5.1.3 Antipsychotic Drug
    • 5.1.4 Antidepressant Drug
    • 5.1.5 Other
  • 5.2 By Mechanism of Action
    • 5.2.1 Selective Serotonin Reuptake Inhibitor
    • 5.2.2 Serotonin Norepinephrine Reuptake Inhibitor
    • 5.2.3 Tricyclic Antidepressant Drug
    • 5.2.4 Beta Blockers
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Allergan PLC
    • 6.1.3 AstraZeneca Plc
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 GlaxoSmithKline Plc
    • 6.1.6 Janssen Pharmaceuticals Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Otsuka Holdings Co. Ltd
    • 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q